ESMO 2024 - Complete program listing (14 programs)

Entire series of daily recaps and interviews from the ESMO 2024

DAY 3

Dr. Tarek Hijal provides key insights from Day 3 of ESMO 2024, focusing on the latest developments in hypofractionated radiotherapy for breast cancer. He discusses significant findings from the Phase III HypoG-01 trial, led by Dr. Sofia Rivera from Gustave Roussy, France. Dr. Hijal explores how these results are poised to impact breast cancer treatment, particularly in optimizing radiotherapy approaches for better patient outcomes.

Watch as Prof. Sibylle Loibl, PI of the PENELOPE-B trial, presents the final overall survival and subgroup analyses for lobular breast cancer patients at ESMO 2024. Gain a detailed overview of the study's key findings and implications.

Dr. Jamil Asselah, along with guests Dr. Kim Ma and Dr. Paolo Tarantino, discuss the morning sessions focused on metastatic and early breast cancer. The panel recaps significant data including insights from the DETECT V trial, KEYNOTE 522, DESTINY-Breast12, and updates from the Natalee trial.

DAY 2

Dr. Jean-Philippe Spano provides a brief history of ESMO's origins and its remarkable growth over the years. He reviews the latest data presented, with a special focus on contributions from his French colleagues and key international studies that have shaped clinical practice in breast cancer oncology.

Dr. Cristina Saura highlights three key messages from the ESMO 2024 meeting, focusing on significant advancements in breast cancer research. First, the results of the DESTINY-Breast12 trial showcased new treatment options for advanced breast cancer. Second, the ICARUS-BREAST01 study provided further insights into innovative therapeutic approaches. Lastly, she emphasized two groundbreaking international studies that confirmed breastfeeding after breast cancer treatment does not increase the risk of recurrence or new cancers, marking an important step for young survivors seeking safe breastfeeding options.

In this video,Dr. Amy Abernethy highlights the transformative potential of AI in oncology and stresses the need for safety and efficacy in patient care. She outlines three key trends essential for scaling AI in the field.

In this video, Dr. Erika Hamilton highlights the latest data on trastuzumab and HER2 testing presented at ESMO 2024. She provides valuable insights into recent advancements and their implications for treatment strategies in HER2-positive cancers.

In this DailyRECAP for September 15th, Dr. Jamil Asselah returns for a second overview of the day’s breast cancer sessions from ESMO 2024, joined by Dr. Rami Younan and Dr. Kim Ma. They focus on key insights from the Presidential Symposium and practice-changing trials.

Dr. Barbara Pistilli, Head of the Breast Pathology Committee at Gustave Roussy, presents the promising results of the Phase II ICARUS-BREAST01 trial at ESMO 2024.

Dr. Peter Schmid presents the long-awaited overall survival data for Pembrolizumab in early-stage triple-negative breast cancer. His insights provide a crucial update on the impact of this therapy, highlighting significant advancements in treatment outcomes.

DAY 1

Join Dr. Asselah, Dr. Younan and Dr. Ma as they review the day's highlights from ESMO 2024

ESMO 2024 - Global Speaker Series - Dr. Nancy Lin on ESMO LBA18: Trastuzumab deruxtecan (T-DXd) in patients with HER2+ advanced/mbc & DESTINYBreast-12 primary results

ESMO 2024 - Global Speaker Series - Dr. Alnouri Highlights What to Expect at ESMO 2024: Advances in Breast Cancer

ESMO 2024 - Global Speaker Series - De-escalation Strategies in HER2+ Early-Stage Breast Cancer with Dr. Carlos A. Gonzalez Nuñez MD